|
1）Nakao K, Itoh H, Saito Y, et al. The natriuretic peptide family. Curr Opin Nephrol Hypertens. 1996; 5: 4-11
|
|
|
|
2）Nigwekar SU, Navaneethan SD, Parikh CR, et al. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009; 4: 261-72
|
|
|
|
|
|
3）Sezai A, Hata M, Niino T, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting. J Am Coll Cardiol. 2011; 58: 898-903
|
|
|
|
|
|
4）Morikawa S, Sone T, Tsuboi H, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009; 53: 1040-6
|
|
|
|
|
|
5）Makino H, Mukoyama M, Mori K, et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia. 2006; 49: 2514-24
|
|
|
|
|
|
6）Ogawa Y, Mukoyama M, Yokoi H, et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol. 2012; 23: 1198-209
|
|
|
|
|
|
7）Kangawa K. Matsuo H. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide(α-ANP). Biochem Biophys Res Commun. 1984; 118: 131-9
|
|
|
|
|
|
8）Garbers DL. Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell. 1992; 71: 1-4
|
|
|
|
|
|
9）Chen W, Oberwinkler H, Wemer F, et al. Atrial natriuretic peptide-mediated inhibition of microcirculatory endothelial Ca2+ and permeability response to histamine involves cGMP-dependent protein kinase I and TRPC6 channels. Arterioscler Thromb Vasc Biol. 2013; 33: 2121-9
|
|
|
|
|
|
10）Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006; 27: 47-72
|
|
|
|
|
|
11）Beltwski J, Wojcicka G. Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Med Sci Monit. 2002; 8: RA39-52
|
|
|
|
|
|
12）Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotension-stimulated proximal tubular sodium and water reabsorption. Nature. 1987; 326: 697-8
|
|
|
|
|
|
13）Suganami T, Mukoyama M, Sugawara A, et al. Overexpression of brain natriuretic peptide in mice ameliorates immune-mediated renal injury. J Am Soc Nephrol. 2001; 12: 2652-63
|
|
|
|
|
|
14）Golos M, Lewko B, Bryl E, et al. Effect of angiotensin II on ANP-dependent guanylyl cyclase A activity in cultured mouse and rat podocytes. Kidney Blood Press Res. 2002; 25: 296-302
|
|
|
|
|
|
15）Kasahara M, Mukoyama M, Sugawara A, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol. 2000; 11: 1691-701
|
|
|
|
|
|
16）Lopez MJ, Wong SK, Kishimoto I, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995; 378: 65-8
|
|
|
|
|
|
17）Tokudome T, Horio T, Kishimoto I, et al. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation. 2005; 111: 3095-104
|
|
|
|
|
|
18）Holtwick R, Gotthardt M, Skryabin B, et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A. 2002; 99: 7142-7
|
|
|
|
|
|
19）Sabrane K, Kruse MN, Fabritz L, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005; 115: 1666-74
|
|
|
|
|
|
20）Surendran K, Simon TC. CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am J Physiol. 2003; 284: F653-62
|
|
|
|
|
|
21）Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87: 1402-12
|
|
|
|
|
|
22）Sezai A, Hata M, Niino T, et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT(Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery)for left ventricular dysfunction. J Am Coll Cardiol. 2010; 55: 1844-51
|
|
|
|
|
|
23）Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998; 31: 674-80
|
|
|
|
|
|
24）Sward K, Valson F, Ricksten SE. Long-term infusion of atrial natriuretic peptide(ANP)improves renal blood flow and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand. 2001; 45: 536-42
|
|
|
|
|
|
25）Hoffmann S, Podlich D, Hahnel B, et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol. 2004; 15: 1475-87
|
|
|
|
|
|
26）Hsu HH, Hoffmann S, Endlich N, et al. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med. 2008; 86: 1379-94
|
|
|
|
|
|
27）Herman-Edelstein M, Thomas MC, Thallas-Bonke V, et al. Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β. Diabetes. 2011; 60: 1779-88
|
|
|
|
|
|
28）Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol. 2009; 297: F1381-90
|
|
|
|
|
|
29）Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone. Roles of oxidative stress and sgk1. Hypertension. 2007; 49: 355-64
|
|
|
|
|
|
30）Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6
|
|
|
|
|
|
31）Kaneshiro Y, Ichihara A, Sakoda M, et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human(pro)renin receptor-transgenic rats. J Am Soc Nephrol. 2007; 18: 1789-95
|
|
|
|
|
|
32）Martin FL, Sangaralingham SJ, Huntley BK, et al. CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PloS One. 2012; 7: e52422
|
|
|
|
|
|
33）Solomon SD, ZIle M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized control trial. Lancet. 2012; 380: 1387-95
|
|
|
|
|